Yahoo · Sep 11, 2026
Revvity to Acquire Human Cell Design to Boost Metabolic Discovery
RVTY's HCD deal is expected to add human pancreatic beta cell models, expanding drug discovery and preclinical research tools for metabolic diseases.
VC
NASDAQ · VCYT
Veracyte, Inc.
Healthcare · Biotechnology
$40.14
Down-$1.07 (-2.60%)
Updated Sep 16, 2026, 8:06 AM
SID Score
4.5/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 3.34B
- P/E ratio
- 109.61
- Dividend yield
- 0.00%
- 52-week range
- $29.46 – $60.91
- Volume
- 1.76M
- Avg. volume
- 966.7K
Price performance
VCYT price history
1M range · 0 trading sessions · Daily adjusted prices
VCYT does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest VCYT news
The latest Smart Investors Daily articles mentioning VCYT.
Stock researchCompany · Overview
VCYT research
Overview
Company profile and research snapshot.
Company profile
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $46.33
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 15, 2026 | Freedom Capital Markets | Buy | — |
| Sep 9, 2026 | UBS | Buy | — |
| Aug 4, 2026 | Piper Sandler | Overweight | — |
| Aug 4, 2026 | Stephens & Co. | Overweight | — |
| Aug 4, 2026 | Morgan Stanley | Underweight | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 11, 2026
IceCure Secures China NMPA Approval for ProSense Cryoablation System
ICCM's NMPA approval for ProSense opens China to commercialization, expanding its global regulatory footprint and long-term revenue opportunity.
Yahoo · Sep 10, 2026
Here's Why You Should Retain Ecolab Stock in Your Portfolio Now
ECL benefits from high-tech growth, digital expansion, innovation and solid Q2 results, while cost fluctuations remain a key concern.
Yahoo · Sep 10, 2026
COO Q3 Earnings Top Estimates, Revenues Miss on Destocking, Stock Down
Cooper Companies' Q3 EPS beats estimates as expense controls offset softer revenues, while U.S. inventory cuts pressure CooperVision and weigh on shares.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
